NCT04060030
Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism
At risk: Primary completion moved 6 months later.
See at-risk trials from Southwest Autism Research & Resource Center
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 11 versions: 11 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion pushed from Jul 31, 2026 to Jan 31, 2027 Show 5 more changesShow less
- Eligibility criteria expanded, about 32 words
- Enrollment closed, study ongoing
- Secondary endpoints: details revised at 13 of 13 entries
- Site details revised at 2 of 2 sites
- Publications: details revised at 5 of 5 entries
- Notable Primary and study completion dates pushed to Jul 31, 2026v10
- Notable Primary completion date: Jan 2025 to Dec 2025
- Study completion date: Jan 2025 to Jun 2026
- Minor Site contacts updated at 2 of 2 sitesv8
- Notable Lead sponsor: Rossignol Medical Center to Southwest Autism Research & Resource Center
- Primary and study completion dates: Dec 2023 to Jan 2025
- Secondary endpoints revised (13)
- Collaborators: 3 to 2
Show 5 earlier versionsHide 5 earlier versions
- Notable Trial status: Active, Not Recruiting to Recruiting
- Site details revised at 2 of 2 sites
Notable Lead sponsor: Phoenix Children's Hospital to Rossignol Medical Centerv5 Show 5 more changesShow less
- Primary and study completion dates: Dec 2022 to Dec 2023
- Eligibility criteria expanded, about 21 words
- Trial status: Recruiting to Active, Not Recruiting
- Study sites revised (2)
- Collaborators: 4 to 3
Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 5 more changesShow less
- Eligibility criteria expanded, about 204 words
- Primary endpoint revised
- Start date changed from estimate of Oct 2020 to Oct 8, 2020
- Secondary endpoints: 12 to 13
- Site details revised at 2 of 2 sites
- Notable Primary and study completion dates: Dec 2021 to Dec 2022
- Start date: May 2020 to Oct 2020
- Notable Start date: Dec 2019 to May 2020v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (13)
Show 8 moreShow less
Arms and interventions
The liquid form of leucovorin calcium will be dosed by weight, with a target dose of 1mg/kg/day, divided into two daily doses. This product may be taken alone or mixed with liquid. Participants randomized to this arm will receive active treatment for both 12-week phases of the study.
The placebo will mimic the experimental treatment in flavor, odor, packaging, and dosing instructions. Participants randomized to this arm will receive placebo for the first 12 weeks of the study, then active treatment for the remaining 12 weeks.
Drugs: Levoleucovorin Calcium
Other: Placebo
Sites
2 sites in 1 country